Representing a global generic pharmaceutical manufacturer in Hatch-Waxman patent litigation relating to the client’s filing of an Abbreviated New Drug Application for authorization to market a generic version of NUBEQA® (darolutamide). We have already obtained for the client dismissal with prejudice of four Orange-Book listed patents.